Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
dc.contributor.author | Badilla‑Porras, R | |
dc.contributor.author | Echeverri‑McCandless, A | |
dc.contributor.author | Weimer, J. M | |
dc.contributor.author | Ulate‑Campos, A | |
dc.contributor.author | Soto‑Rodríguez, A | |
dc.contributor.author | Gutiérrez‑Mata, A | |
dc.contributor.author | Hernández‑Con, L | |
dc.contributor.author | Bogantes‑Ledezma, S | |
dc.contributor.author | Balmaceda‑Meza, A | |
dc.contributor.author | Brudvig, J | |
dc.contributor.author | Sanabria‑Castro, A | |
dc.date.accessioned | 2025-07-14T20:47:35Z | |
dc.date.available | 2025-07-14T20:47:35Z | |
dc.date.issued | 2022 | |
dc.description | ARTICULO | |
dc.description.abstract | Background: Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population. Objective: To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children’s Hospital in Costa Rica and to characterize via molecular testing their causative mutations. Methods: DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants’ sociodemographic and clinical characteristics were also obtained from their medical records. Results: Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens. Conclusions: This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies | |
dc.description.sponsorship | Los autores | |
dc.identifier.other | doi.org/10.1186/s13023-021-02162-z | |
dc.identifier.uri | http://hdl.handle.net/20.500.11764/4912 | |
dc.language.iso | en | |
dc.publisher | Los autores | |
dc.relation.ispartofseries | Orphanet Journal of Rare Diseases; v. 17:13 2022 | |
dc.subject | LIPOFUSCINOSIS CEROIDEAS NEURONALES | |
dc.subject | Enfermedades por Almacenamiento Lisosomal | |
dc.title | Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience | |
dc.type | Article |